Drug Discovery

FDA grants breakthrough therapy status to Eli Lilly’s olomorasib

Eli Lilly has received the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, an investigational KRAS G12C inhibitor.

OMass signs deal with Genentech for IBD small molecules

OMass Therapeutics in the UK has signed an exclusive collaboration and licensing agreement with Roche Group member Genentech to develop and commercialise inflammatory bowel disease (IBD) therapies.

Biosynth opens expanded GMP bioconjugation facility in Germany

Biosynth, a supplier of essential raw materials and services for the life sciences and diagnostics sectors, has opened an expanded good manufacturing practice (GMP) bioconjugation facility at its Berlin site in Germany.

Salipro Biotech collaborates with Daewoong for new therapies development

Salipro Biotech has announced a research collaboration with Daewoong Pharmaceutical, focusing on the development of new small molecule drugs.

PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea

PCI Pharma Services (PCI) has concluded the acquisition of Ajinomoto Althea, a sterile fill-finish contract development and manufacturing organisation (CDMO) based in the US.

Parvus and Resilience expand partnership to develop IBD drug candidate

Clinical-stage company Parvus Therapeutics has expanded its collaboration with biomanufacturing company National Resilience to develop and manufacture the autoimmune drug candidate, PVT401, for inflammatory bowel disease (IBD).

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.

insitro collaborates with Lilly on metabolic disease treatments

Machine learning-enabled drug discovery and development company insitro has executed three agreements with Lilly to advance new treatments for metabolic diseases.

PsychoGenics secures NIH contract to identify new pain therapeutics

Preclinical contract research organisation (CRO) PsychoGenics has received an award from the US National Institutes of Health (NIH) to conduct the testing and identification of new investigational therapeutics aimed at treating pain.